A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma.

MLA

Ding, Yangyang, et al. “A Bruton Tyrosine Kinase Inhibitor-Resistance Gene Signature Predicts Prognosis and Identifies TRIP13 as a Potential Therapeutic Target in Diffuse Large B-Cell Lymphoma.” Scientific Reports, vol. 14, no. 1, Sept. 2024, pp. 1–15. EBSCOhost, https://doi.org/10.1038/s41598-024-72121-8.

APA

Ding, Y., Huang, K., Sun, C., Liu, Z., Zhu, J., Jiao, X., Liao, Y., Feng, X., Guo, J., Zhu, C., Zhai, Z., & Xiong, S. (2024). A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma. Scientific Reports, 14(1), 1–15. https://doi.org/10.1038/s41598-024-72121-8

Chicago

Ding, Yangyang, Keke Huang, Cheng Sun, Zelin Liu, Jinli Zhu, Xunyi Jiao, Ya Liao, et al. 2024. “A Bruton Tyrosine Kinase Inhibitor-Resistance Gene Signature Predicts Prognosis and Identifies TRIP13 as a Potential Therapeutic Target in Diffuse Large B-Cell Lymphoma.” Scientific Reports 14 (1): 1–15. doi:10.1038/s41598-024-72121-8.